Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell
Authors not listed
University of Göttingen · 2012
Abstract
Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-03 MST
Cite this
APA
Anonymous. (2012). Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell. <em>University of Göttingen</em>. https://clinicaltrials.gov/study/NCT01686321
Vancouver
Anonymous. Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell. University of Göttingen. 2012.
BibTeX
@misc{anon2012Subcut,
title = {Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell},
author = {Anonymous},
journal = {University of Göttingen},
year = {2012},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Composite Interceptive Med Science 2018
Open access · US-GOV
Clinical Evaluation of Turmeric and Tulsi Polyherbal Formulation in the Management of Frailty in Elderly Population: An Open Label Randomized Controlled Trial
University of Milano Bicocca 2020
Open access · US-GOV
Relationship Between Frailty and Clinical Outcomes in Elderly Patients With COVID-19
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 2025
Open access · US-GOV
AZA Combined with R-GemOx for the Initial Treatment of Elderly DLBCL: an Open, Single-arm, Multicenter Clinical Study
Federico II University 2022
Open access · US-GOV
Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients
Shen Lin 2013
Open access · US-GOV
Sequential Paclitaxel Chemotherapy and Radiotherapy as First Line Treatment for Elderly Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial
Xiaohui He 2025
Open access · US-GOV